Clinical trials: Type 2 Diabetes (T2D)
Diabetes Mellitus, Type 2
RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus
The purpose of this study is to test the hypothesis that re-treatment of the duodenal mucosa with RF vapor ablation will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation)…
- Trial name
- NCT06724822
- Testing
- RF Vapor Ablation
- Where
- Chile
- Volunteers
- 12 people
- Sponsor
- Aqua Medical, Inc.
Type 2 Diabetes Mellitus
VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
The purpose of this study was to determine whether the initiation of a vildagliptin plus metformin combination regimen would result in more durable glycemic control than metformin monotherapy in treatment-naïve patients with…
- Trial name
- NCT01528254
- Testing
- vildagliptin, Metformin
- Where
- 227 sites in Argentina, Australia and 32 more
- Volunteers
- 2,004 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT03406377
- Testing
- OPK-88003
- Where
- 3 sites in United States
- Volunteers
- 113 people
- Sponsor
- OPKO Health, Inc.
Diabetes Mellitus, Type 2
A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM
The purpose of the proposed work is to assess the effects of a dietary supplement, containing chromium (600 mcg per day) provided by chromium picolinate and biotin (2 mg per day) on glycemic control in type 2 diabetes.
- Trial name
- NCT00308451
- Testing
- Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Nutrition 21, Inc.
Healthy
Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.
- Trial name
- NCT01156246
- Testing
- Dapagliflozin/Metformin
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia
The purpose of the study is to collect information on how Tresiba® works in real world patients with Diabetes Mellitus, Type 2 (type 2 diabetes). Participants will get Tresiba® as prescribed by their doctor.
- Trial name
- NCT04315688
- Testing
- insulin degludec
- Where
- 40 sites in Russia
- Volunteers
- 494 people
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations
The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.
- Trial name
- NCT06996886
- Testing
- AZD5004
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
- Trial name
- NCT04285983
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Takeda
Hypertension
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.
- Trial name
- NCT00325962
- Testing
- 6R-BH4 (sapropterin dihydrochloride)
- Where
- 24 sites in United States
- Volunteers
- 84 people
- Sponsor
- BioMarin Pharmaceutical
Type 2 Diabetes Mellitus
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT06982846
- Testing
- Retatrutide
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in South America. The aim of this trial is to evaluate the efficacy of metformin plus biphasic insulin aspart or insulin NPH on blood glucose control in subjects with type 2 diabetes.
- Trial name
- NCT00592969
- Testing
- metformin, biphasic insulin aspart
- Where
- 2 sites in Argentina, Brazil
- Volunteers
- 164 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 187004 following multiple dose administration over 14 days.
- Trial name
- NCT01874483
- Testing
- BI 187004
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
Participants will be randomly assigned to either a positive affect skills intervention or a psychoeducation control group and assessed with questionnaires before, during, and after the 8-week program, as well as at 3 months, 6…
- Trial name
- NCT04068805
- Testing
- Happify
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Happify Inc.
Type 2 Diabetes
A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)
This study is a six-month, prospective, randomized, multicenter, single- blind, controlled clinical study to evaluate the effect of three low-doses of Naturlose (Tagatose) on glycemic control and safety in subjects with Type 2…
- Trial name
- NCT00961662
- Testing
- D-Tagatose
- Where
- 13 sites in United States, India
- Volunteers
- 161 people
- Sponsor
- Robert Lodder
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
- Trial name
- NCT07064486
- Testing
- BGM0504, Semaglutide
- Where
- 4 sites in Indonesia
- Volunteers
- 152 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control.
- Trial name
- NCT01177813
- Testing
- BI 10773, BI 10773 open label
- Where
- 124 sites in United States, Belgium and 7 more
- Volunteers
- 986 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously…
- Trial name
- DUAL™ (NCT02100475)
- Testing
- insulin degludec/liraglutide, insulin aspart
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes Mellitus
The subjects of this study are patients with type 2 diabetes mellitus. The patients take part in dietetic therapy and exercise therapy, and also receive diabetes education to improve lifestyle habits, but since diet and exercise…
- Trial name
- NCT06156696
- Testing
- BAP0527, Blood Glucose Meter
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Angina Pectoris, Coronary Artery Disease
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- TERISA (NCT01425359)
- Testing
- Ranolazine
- Where
- 135 sites in United States, Belarus and 12 more
- Volunteers
- 949 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.